Table 1A.
Cross-reactivity profile of anti-hTNF-alpha VNAR lead constructs compared to commercially available anti-hTNF-alpha mAbs and a pre-clinical VHH TNF30 domain. (A). Binding (B) and Neutralization (N) data obtained in our laboratory.
|
Human (bind/neutralize) B/N |
Dog (B/N) |
Cynomolgus (B/N) |
Rat (B/N) |
Mouse (B/N) |
Rabbit (B/N) |
Pig (B/N) |
Human TNF-β (B/N) |
|
|---|---|---|---|---|---|---|---|---|
| Lead anti-hTNF-α VNARs (D1 & C4) | +++/+++ | +++/+++ | +++/+++ | –/– | –/– | –/– | –/– | –/– |
| TNF30 (VHH) |
+++/+++ | +++/+++ | +++/+++ | –/– | –/– | –/– | +/+ | ++/– |
| Adalimumab (Humira®) |
+++/+++ | +++/+++ | +++/+++ | –/– | ++/++ | –/– | –/– | –/– |
+++ denotes strong binding/neutralization activity, ++ moderate; + very weak activity and—denotes no binding/neutralization activity observed. Binding (B) and Neutralization (N). TNF30 is an anti-TNF-α Nanobody™ previously reported in Beirnaert (31).